- Supported exchanges /
- F /
- 8EV.F
EVGEN PHARMA PLC LS-0025 (8EV F) stock market data APIs
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
EVGEN PHARMA PLC LS-0025 Financial Data Overview
| 0.0005 | |
| 0.0005 | |
| - | |
| 0.0005 | |
| 0.0005 | |
| 0.0005-0.007 | |
| 3 203 K | |
| 427 M | |
| 396 K | |
| 1.418 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
EVGEN PHARMA PLC LS-0025 Fundamental Data is available in our Financial Data APIs
- Net Revenue 396 K
- EBITDA -3 555 000
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get EVGEN PHARMA PLC LS-0025 Earnings via APIs
- Latest Release 2024-10-30
- EPS/Forecast NaN
Get EVGEN PHARMA PLC LS-0025 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
